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Letter to the Editor
Safety and efficacy of oral anticoagulants in atrial fibrillation and bioprosthetic heart valves
Dear Editors,
Atrial fibrillation (AF) is commonly encountered in clinical practice
by internists and specialists, both in the inpatient and ambulatory set
tings. AF increases the risk of stroke or systemic embolisation (SSE) and
heightens the associated morbidity and mortality [1]. Warfarin and
direct oral anticoagulants (DOACs) have shown benefit in reducing SSE
events in patients with AF; however, studies that established the
non-inferiority of DOACs compared with warfarin included patients
with non-valvular atrial fibrillation (NVAF) [2–5]. These studies
generally excluded patients with significant mitral stenosis or a pros
thetic heart valve. Although the current approval of DOACs is limited to
patients with NVAF, a small proportion of patients in their clinical trials
had a bioprosthetic heart valve (BPHV) [6,7]. The prevention of SSE
with DOACs in AF patients with a BPHV remained an area of uncertainty
until the recent Rivaroxaban for Valvular Heart Disease and Atrial
Fibrillation (RIVER) study demonstrated that rivaroxaban was non
inferior to warfarin for prevention of SSE among patients with AF or
atrial flutter and a bioprosthetic mitral valve [8]. The objective of our
study is to strengthen the evidence by comparing the efficacy and safety
of DOACs as a class with warfarin in AF patients with a BPHV by
reviewing all available data in this population.
PubMed and Embase were searched from inception through
November 2020 for keywords ‘non-vitamin K antagonist oral anticoag
ulants’ or ‘direct oral anticoagulants’ or ‘dabigatran’ or ‘rivaroxaban’ or
‘apixaban’ or ‘edoxaban’ AND ‘stroke’ or ‘systemic embolism’ or ‘mor
tality’ or ‘major bleeding’ or ‘cardiovascular mortality’ AND ‘bio
prosthetic heart valve”, with the limits for humans and RCTs activated.
The Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines were followed (Supplemental Fig. 1).
Outcomes of interest were SSE, all-cause mortality, cardiovascular
mortality, and major bleeding. A fixed effect and a random-effects metaanalysis (using the generic inverse variance method to account for the
expected clinical and methodological heterogeneity among trials) was
performed. Results are presented as ORs with 95% confidence intervals
(CIs). Methodology is further discussed in the online supplement.
Our initial search yielded 865 articles. After deduplication on title
review, 746 studies remained. The abstract review led to the exclusion of
the least relevant articles, and we selected seven articles for the final
full-text review. On full-text review, we determined that there were four
RCTs that had data comparing DOACs in 1,285 AF patients with a BPHV
and in which quantitative analysis was possible [6–9]. Table 1 shows the
baseline characteristics of patients in the included trials, respectively.
The studies included were generally free from significant bias other than
RIVER and DAWA which had an open-label design that contributed to a
high risk for detection and attrition bias (Supplemental Fig. 2).
All four trials reported outcomes of SSE and major bleeding. Among
patients with AF and a BPHV, DOAC treatment compared with warfarin

treatment was associated with a 57% significant reduction in the odds of
SSE (OR 0.43; 95% CI 0.20–0.94, p=0.04; I2 =11%); Fig. 1 panel A. For
major bleeding, DOAC treated patients had a similar odds of outcome
compared with warfarin-treated patients (OR 0.80, 95% CI 0.59-1.08;
p=0.15; I2=0%); Fig. 1 panel B. Data for the all-cause mortality
outcome was available in three studies (1,188 randomised patients).
Analysis of these 3 studies demonstrated that DOAC treated patients had
a similar odds for all-cause mortality than warfarin-treated patients (OR
0.95; 95% CI 0.55-1.62; p=0.83; I2=0%); Fig. 1 panel C. Data for the
cardiovascular mortality outcome was available in two studies (1,161
randomised patients). Analysis of these 2 studies demonstrated that
DOAC treated patients had a similar odds for cardiovascular mortality
than warfarin-treated patients (OR 0.84; 95% CI 0.40-1.79; p=0.65;
I2=0%); Fig. 1 panel D.
Patients with AF and a BPHV are commonly encountered in clinical
practice. Warfarin is the most frequently utilised anticoagulation ther
apy in this patient population and recent data from the United States
suggests a prevailing off-label use of DOACs in patients with BPHV [10].
Adverse drug events from warfarin use have significant health care
consequences related to bleeding events and associated hospitalizations.
An uncertainty exists regarding the most effective anticoagulation
therapy in this patient population as only few studies compared DOACs
with warfarin in these patients and the availability of adequate and
satisfactory safety data with DOAC use in this population is lacking. In
addition, the lack of a validated SSE risk assessment tool in patients with
BPHV could also contribute to this problem. Recently, the CHA2DS2
VASC score was found to yield comparable SSE risk estimated for pa
tients with AF and a BPHV and those with NVAF [1]. As such, long-term
anticoagulation in AF patients with a BPHV could perhaps be managed
similarly to patients with NVAF, pending results from appropriately
designed randomized clinical trials in the BPHV patient population to
provide assuring data regarding the overall clinical efficacy and safety of
DOACs over warfarin. The results of this meta-analysis should further
increase confidence among practitioners that patients with AF and
BPHV could be safely and effectively treated with DOACs. Our study
findings support such an approach and further emphasize the urgent
need for a well-designed clinical trial.
A major limitation of the current study is that one trial (RIVER)
contributed almost 80% of the study population. Two of the studies
included were smaller post-hoc analyses of randomised control trial data
and once was a very small single center pilot study with a short follow up
duration. In addition, studies included in the meta-analysis other than
the RIVER trial were not powered to detect differences in the outcomes
studied in patients with BPHV. Although these limitations might suggest
that the RIVER study results primarily drive the findings of this metaanalysis, a prior analysis of ours based on the three earlier smaller an
alyses demonstrated similar findings for the outcomes [1]. The CIs were
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Table 1
Randomised controlled trials and substudies that compared direct oral anticoagulants with warfarin in patients with atrial fibrillation and bioprosthetic heart valve.
Study name
Study design
BPHV studies
Intervention vs Warfarin
BPHV patients
Median Follow up (years)
TTR (%)
Mean CHADS2 score
Mean HAS-BLED
Median age (years)
Hypertension (%)
Previous stroke, TIA or systemic embolization (%)
Diabetes Mellitus (%)
EVENTS [N]
Stroke or systemic embolization
Major bleeding
All-cause death
Cardiovascular death

ARISTOTLE
Substudy of double-blind RCT
Guimarães et al, 2019
Apixaban
104
1.8
NA*
NA*
NA*
78
98
18
NA*
Apixaban
Warfarin
4
2
7
7
7
6
2
2

DAWA
Open-label RCT
Duares et al, 2016
Dabigatran 110 mg
27
0.3
66.5
NA*
NA*
44.8
48.4
30
3.6
Dabigatran
Warfarin
0
1
1
2
0
1
NA

ENGAGE AF-TIMI 48
Substudy of double-blind RCT
Carnicelli et al, 2017
Edoxaban
191
2.8
68.9
3.0
2.7
75
NA*
20.9
NA*
Edoxaban
Warfarin
NA
0.76%/year
6.27%/year
NA
NA

RIVER
Double-blind open-label RCT
Guimarães et al, 2020
Rivaroxaban
1,005
1
65.5
2.6
1.6
59
61
15.3
13.7
Rivaroxaban
Warfarin
3
14
7
13
20
20
11
13

CHADS2 congestive heart failure, hypertension, age, diabetes mellitus, stroke/thromboembolism.
HAS-BLED hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly, drugs/alcohol.
NA=Not available; BPHV=bioprosthetic heart valve; TTR=time in therapeutic range; TIA=transient.

Fig. 1. (A) Stroke or systemic embolisation in patients with AF and BPHV. (B) Major bleeding in patients with AF and BPHV. (C) All-cause mortality in patients with
AF and BPHV. (D) Cardiovascular mortality in patients with AF and BPHV. AF, atrial fibrillation; BPHV, bioprosthetic heart valve.
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References

wide for all the outcomes studied, suggesting a low statistical power for
these comparisons. The position of the BPHV could have varied between
the studies. The RIVER study included only patients with a BPHV in the
mitral position, whereas the other studies did not provide data regarding
the position of the BPHV. Given these limitations, our study findings
should be considered hypothesis-generating for the non-inferiority of
DOACs as a group compared to warfarin in AF patients with a BPHV at
any location. Confirmation of these findings in the overall BPHV patient
population with concomitant AF is an urgent necessity to provide safe
and effective anticoagulation therapies.
In conclusion, our data suggest that DOACs as a class have similar
efficacy and safety compared with warfarin in patients with AF and a
BPHV. DOACs were associated with a modest but statistically significant
reduction in SSE than warfarin in this population. Future RCTs that will
evaluate the role of individual DOACs in this high-risk patient popula
tion are needed to ascertain our findings and to provide appropriate
clinical guidance to effectively manage this high-risk patient population.
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